Pfizer Rounds Out Zyrtec Line With Chewable Tablet NDA Approval
This article was originally published in The Tan Sheet
Executive Summary
Pfizer hopes to increase pediatric use of its Rx allergy drug Zyrtec (cetirizine) with new 5 mg and 10 mg chewable tablets formulations, to be available starting in late April and moving to full distribution in early summer
You may also be interested in...
Antihistamine Price Erosion Justifies Forced Switch – WellPoint
WellPoint Health Networks is continuing its campaign to urge a forced Rx-to-OTC switch of low-and non-sedating antihistamines cetirizine, fexofenadine and desloratadine
Antihistamine Price Erosion Justifies Forced Switch – WellPoint
WellPoint Health Networks is continuing its campaign to urge a forced Rx-to-OTC switch of low-and non-sedating antihistamines cetirizine, fexofenadine and desloratadine
Antihistamine Price Erosion Justifies Forced Switch – WellPoint
WellPoint Health Networks is continuing its campaign to urge a forced Rx-to-OTC switch of low-and non-sedating antihistamines cetirizine, fexofenadine and desloratadine